Test Story

By: NewsUSA

March 27, 2025 at 20:00 PM EDT

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Symbol	Price	Change (%)
AMZN	208.63	+0.24 (0.12%)
AAPL	262.85	-1.87 (-0.71%)
AMD	191.65	-6.97 (-3.51%)
BAC	50.32	+0.51 (1.02%)
GOOG	301.78	-4.58 (-1.49%)
META	655.73	+2.17 (0.33%)
MSFT	405.14	+6.59 (1.65%)
NVDA	179.85	-2.63 (-1.44%)
ORCL	149.85	+0.60 (0.40%)
TSLA	393.17	-10.15 (-2.52%)

Symbol

Price

Change (%)

AMZN

208.63

+0.24 (0.12%)

AAPL

262.85

-1.87 (-0.71%)

AMD

191.65

-6.97 (-3.51%)

BAC

50.32

+0.51 (1.02%)

GOOG

301.78

-4.58 (-1.49%)

Test Story

More News

Recent Quotes

Resources